CLL Clinical Trials

74 clinical trials for CLL across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL — RECRUITING · PHASE3
• A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. — RECRUITING · PHASE1
• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors — RECRUITING · PHASE3
• A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). — RECRUITING · PHASE3
• Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms — RECRUITING · PHASE1
• Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) — RECRUITING
• A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies — RECRUITING · PHASE1
• Study of the Metabolism in the Lymphatic Niche of CLL — RECRUITING
• A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients — RECRUITING · PHASE2
• Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma — RECRUITING · PHASE1
• CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL — RECRUITING · NA
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation — RECRUITING · PHASE2
• Study of Epcoritamab as a Consolidation Therapy in CLL/SLL — RECRUITING · PHASE2
• Registry of the German CLL Study Group — RECRUITING
• Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL — RECRUITING · NA
• A Phase I Dose Finding Study of MB-CART2219.1 — RECRUITING · PHASE1
• Real-world Study of Acalabrutinib — RECRUITING
• Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia — RECRUITING · PHASE1
• Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia — RECRUITING
• Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment — RECRUITING · PHASE2
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — ACTIVE_NOT_RECRUITING · PHASE3
• A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies — NOT_YET_RECRUITING · NA
• Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). — NOT_YET_RECRUITING · PHASE2
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies — COMPLETED · PHASE1
• Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) — COMPLETED
• PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL — NOT_YET_RECRUITING · PHASE1
• Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia — COMPLETED · PHASE1
• Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia — ACTIVE_NOT_RECRUITING
• A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma — WITHDRAWN
• A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives — TERMINATED · PHASE2
• Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors — COMPLETED · PHASE1
• Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL — COMPLETED · PHASE1
• The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China — NOT_YET_RECRUITING
• Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) — COMPLETED · PHASE2
• Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia — TERMINATED · PHASE1
• The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China — OTHER
• Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) — COMPLETED
• Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL — COMPLETED · PHASE2
• Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL — TERMINATED · PHASE1
• A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) — OTHER · PHASE1
• Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL — TERMINATED · PHASE2
• A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. — OTHER · PHASE1
• Hypertension Management in Cancer Patients — TERMINATED · NA
• Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia — COMPLETED · PHASE4
• Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) — COMPLETED · PHASE2
• Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL — WITHDRAWN · PHASE2
• A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia — COMPLETED

Refine this search